JP2004504038A - 多発性嚢胞腎疾患の検出と治療 - Google Patents

多発性嚢胞腎疾患の検出と治療 Download PDF

Info

Publication number
JP2004504038A
JP2004504038A JP2002512419A JP2002512419A JP2004504038A JP 2004504038 A JP2004504038 A JP 2004504038A JP 2002512419 A JP2002512419 A JP 2002512419A JP 2002512419 A JP2002512419 A JP 2002512419A JP 2004504038 A JP2004504038 A JP 2004504038A
Authority
JP
Japan
Prior art keywords
seq
nos
nucleotide
pkd1
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002512419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004504038A5 (https=
Inventor
ジェルミノ　グレゴリー　ジー．
ワトニック　テリー　ジェイ．
ファクディーキッチャレン　バンヤン
Original Assignee
ザ　ジョンズ　ホプキンス　ユニバーシティー　スクール　オブ　メディシン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ　ジョンズ　ホプキンス　ユニバーシティー　スクール　オブ　メディシン filed Critical ザ　ジョンズ　ホプキンス　ユニバーシティー　スクール　オブ　メディシン
Publication of JP2004504038A publication Critical patent/JP2004504038A/ja
Publication of JP2004504038A5 publication Critical patent/JP2004504038A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2002512419A 2000-07-13 2001-07-13 多発性嚢胞腎疾患の検出と治療 Pending JP2004504038A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21826100P 2000-07-13 2000-07-13
US28369101P 2001-04-13 2001-04-13
PCT/US2001/022035 WO2002006529A2 (en) 2000-07-13 2001-07-13 Detection and treatment of polycystic kidney disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011224456A Division JP5536005B2 (ja) 2000-07-13 2011-10-12 多発性嚢胞腎疾患の検出と治療

Publications (2)

Publication Number Publication Date
JP2004504038A true JP2004504038A (ja) 2004-02-12
JP2004504038A5 JP2004504038A5 (https=) 2007-01-18

Family

ID=26912733

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002512419A Pending JP2004504038A (ja) 2000-07-13 2001-07-13 多発性嚢胞腎疾患の検出と治療
JP2011224456A Expired - Fee Related JP5536005B2 (ja) 2000-07-13 2011-10-12 多発性嚢胞腎疾患の検出と治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011224456A Expired - Fee Related JP5536005B2 (ja) 2000-07-13 2011-10-12 多発性嚢胞腎疾患の検出と治療

Country Status (5)

Country Link
US (4) US7553644B2 (https=)
JP (2) JP2004504038A (https=)
AU (1) AU2001271998A1 (https=)
CA (2) CA2395781C (https=)
WO (1) WO2002006529A2 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009544314A (ja) * 2006-07-24 2009-12-17 アテナ ダイアグノスティックス，インコーポレイテッド Ｐｋｄの変異およびその評価
WO2012060109A1 (en) 2010-11-05 2012-05-10 Kyoto University Method of examining polycystic kidney disease and method of screening for therapeutic agent of the disease
JP2012112784A (ja) * 2010-11-24 2012-06-14 Tohoku Univ 染色体優性多発性嚢胞腎の判定方法及び予防・治療薬のスクリーニング方法
WO2016035168A1 (ja) * 2014-09-03 2016-03-10 大塚製薬株式会社 病態判定支援装置、方法、プログラムおよび記録媒体
WO2016080299A1 (ja) * 2014-11-19 2016-05-26 大塚製薬株式会社 Ｐｋｄ１遺伝子及びｐｋｄ２遺伝子のエクソンを増幅するためのプライマーセット及び方法

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2395781C (en) * 2000-07-13 2010-04-13 The Johns Hopkins University School Of Medicine Detection and treatment of polycystic kidney disease
US6916619B2 (en) 2001-10-12 2005-07-12 Athena Diagnostics, Inc. Compositions and methods for genetic analysis of polycystic kidney disease
US7273701B2 (en) 2001-10-12 2007-09-25 Athena Diagnostics, Inc. Compositions and methods for genetic analysis of polycystic kidney disease
GB0215509D0 (en) * 2002-07-04 2002-08-14 Novartis Ag Marker genes
US20050090001A1 (en) 2003-10-07 2005-04-28 Parker Stephen H. Cell lines and methods for producing proteins
US7141376B2 (en) * 2004-05-28 2006-11-28 Lyons Leslie A Carrier tests for polycystic kidney disease in the cat
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
EP2142498A2 (en) * 2007-04-02 2010-01-13 Institute for Oneworld Health Cftr inhibitor compounds and uses thereof
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
WO2009131957A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
JP2012503005A (ja) * 2008-09-19 2012-02-02 インスティテュート フォア ワンワールド ヘルス イミダゾール誘導体およびトリアゾール誘導体を含む、化合物、組成物ならびに方法。
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
WO2013019169A1 (en) 2011-08-01 2013-02-07 Institute For Oneworld Health Phosphate prodrugs
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
AU2015327836B2 (en) 2014-10-03 2021-07-01 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
ES2933674T3 (es) 2015-03-13 2023-02-13 Univ Indiana Res & Tech Corp Inhibidores de PDE5 para uso en la reducción del tamaño del quiste renal y/o prevención del crecimiento del quiste renal
CN104975081B (zh) * 2015-06-01 2019-03-01 南京市妇幼保健院 检测pkd1基因突变的扩增引物、试剂盒及其检测方法
CN108603230A (zh) 2015-10-09 2018-09-28 南安普敦大学 基因表达的调节与蛋白质表达失调的筛选
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
WO2017106377A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
CN106995851B (zh) * 2017-04-25 2020-07-03 郑州大学第一附属医院 扩增pkd1外显子超长片段的pcr引物、检测pkd1基因突变的试剂盒及应用
KR102318434B1 (ko) 2017-08-25 2021-11-01 스톡 테라퓨틱스, 인크. 병태 및 질환 치료용 안티센스 올리고머
DE102018103215B3 (de) * 2018-02-13 2019-08-14 Gna Biosolutions Gmbh Verfahren und Vorrichtung zur Extraktion einer Nukleinsäure aus einer Probenflüssigkeit
CA3099280A1 (en) 2018-05-04 2019-11-07 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
AU2020227825B2 (en) 2019-02-27 2026-03-26 Stoke Therapeutics, Inc. Antisense oligomers for treatment of conditions and diseases
CN115867657A (zh) 2020-05-11 2023-03-28 斯托克制药公司 用于治疗疾患和疾病的opa1反义寡聚物
CA3208118A1 (en) * 2021-01-14 2022-07-21 Mayo Foundation For Medical Education And Research Treating diseases and improving nucleic acid delivery
JP2025519109A (ja) * 2022-05-25 2025-06-24 イエール ユニバーシティ 多発性嚢胞腎および多発性嚢胞肝を処置、緩和、および／または防止する方法
CN116179683B (zh) * 2022-12-29 2025-02-28 阅尔基因技术（苏州）有限公司 一种检测人类pkd1基因变异的探针和引物组合物及其应用
EP4728074A2 (en) * 2023-06-13 2026-04-22 Nephrogen Inc. Systems, methods, and compositions for de-repressing pkd1
CN116732168B (zh) * 2023-08-04 2023-11-03 北京贝瑞和康生物技术有限公司 检测常染色体显性多囊肾多种突变的方法和试剂盒
CN117143997B (zh) * 2023-10-31 2024-02-23 北京中仪康卫医疗器械有限公司 一种用于pkd1基因突变检测的引物组、试剂盒及检测方法
CN118745460B (zh) * 2024-08-05 2025-07-11 英科新创（苏州）生物科技有限公司 猫pkd1基因突变位点的应用及试剂和诊断试剂盒

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
DE69433811T2 (de) * 1993-01-07 2005-06-23 Sequenom, Inc., San Diego Dns - sequenzierung durch massenspektronomie
US5837832A (en) * 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5472672A (en) * 1993-10-22 1995-12-05 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and method for polymer synthesis using arrays
AU1322795A (en) 1993-12-24 1995-07-17 Erasmus University Rotterdam Tuberous sclerosis 2 gene and uses thereof
US5654170A (en) * 1994-10-12 1997-08-05 Johns Hopkins University Polycystic kidney disease gene
US6867288B1 (en) * 1994-10-12 2005-03-15 Genzyme Corporation Polycystic kidney disease gene
US6071717A (en) * 1995-01-31 2000-06-06 Genzyme Corporation Polycystic kidney disease gene and protein
EP0914441A2 (en) * 1996-04-23 1999-05-12 The Wistar Institute Of Anatomy And Biology Novel human cytomegalovirus dna constructs and uses therefor
US6031088A (en) 1996-05-23 2000-02-29 Albert Einstein College Of Medicine Of Yeshiva University Polycystic kidney disease PKD2 gene and uses thereof
AU3211997A (en) * 1996-05-24 1997-12-09 Genzyme Corporation Polycystic kidney disease gene
US6234964B1 (en) * 1997-03-13 2001-05-22 First Opinion Corporation Disease management system and method
US6297010B1 (en) * 1998-01-30 2001-10-02 Genzyme Corporation Method for detecting and identifying mutations
US6362326B1 (en) * 1998-12-22 2002-03-26 Smithkline Beecham Corporation 11 cby genomic sequence
IT1304060B1 (it) * 1998-12-29 2001-03-07 St Microelectronics Srl Variatore di livello per circuiteria a tensione d'alimentazionemultipla
CA2395781C (en) * 2000-07-13 2010-04-13 The Johns Hopkins University School Of Medicine Detection and treatment of polycystic kidney disease

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009544314A (ja) * 2006-07-24 2009-12-17 アテナ ダイアグノスティックス，インコーポレイテッド Ｐｋｄの変異およびその評価
WO2012060109A1 (en) 2010-11-05 2012-05-10 Kyoto University Method of examining polycystic kidney disease and method of screening for therapeutic agent of the disease
JP2012112784A (ja) * 2010-11-24 2012-06-14 Tohoku Univ 染色体優性多発性嚢胞腎の判定方法及び予防・治療薬のスクリーニング方法
WO2016035168A1 (ja) * 2014-09-03 2016-03-10 大塚製薬株式会社 病態判定支援装置、方法、プログラムおよび記録媒体
JPWO2016035168A1 (ja) * 2014-09-03 2017-06-29 大塚製薬株式会社 病態判定支援装置、方法、プログラムおよび記録媒体
WO2016080299A1 (ja) * 2014-11-19 2016-05-26 大塚製薬株式会社 Ｐｋｄ１遺伝子及びｐｋｄ２遺伝子のエクソンを増幅するためのプライマーセット及び方法
US10538812B2 (en) 2014-11-19 2020-01-21 Otsuka Pharmaceutical Co., Ltd. Primer set and method for amplifying exons of PKD1 gene and PKD2 gene

Also Published As

Publication number Publication date
WO2002006529A3 (en) 2003-06-26
JP2012070736A (ja) 2012-04-12
US20060246504A1 (en) 2006-11-02
AU2001271998A1 (en) 2002-01-30
CA2697031C (en) 2017-10-31
US20030008288A1 (en) 2003-01-09
US20140037652A1 (en) 2014-02-06
US8530161B2 (en) 2013-09-10
CA2697031A1 (en) 2002-01-24
JP5536005B2 (ja) 2014-07-02
US9670543B2 (en) 2017-06-06
CA2395781A1 (en) 2002-01-24
WO2002006529A2 (en) 2002-01-24
US7553644B2 (en) 2009-06-30
US20170321278A1 (en) 2017-11-09
CA2395781C (en) 2010-04-13

Similar Documents

Publication Publication Date Title
JP5536005B2 (ja) 多発性嚢胞腎疾患の検出と治療
WO1995034573A9 (en) Identification of polycystic kidney disease gene, diagnostics and treatment
US20100129824A1 (en) Distinguishing pca3 messenger rna species in benign and malignant prostate tissues
US20040132021A1 (en) Osteolevin gene polymorphisms
CN1643148B (zh) 小鼠精子形成基因、人男性不育关连基因、以及利用该基因的诊断系统
JP2004504802A (ja) 骨粗鬆症の診断および療法
WO2003054166A2 (en) Nucleotide polymorphisms associated with osteoarthritis
JP2004505631A (ja) リシルオキシダーゼ遺伝子ファミリーの新規メンバー
JP2012095651A (ja) ラフォラ病遺伝子
WO1999007835A2 (en) 1-alpha-hydroxylase
US6403307B1 (en) Glaucoma therapeutics and diagnostics
KR20170041955A (ko) 근위축성측삭경화증에 대한 진단 마커로서의 돌연변이 유전자 및 이를 이용한 진단방법
EP2245041B1 (en) Compositions and methods for detecting juvenile renal dysplasia or calcium oxalate stones in dogs
US8361723B2 (en) Keratin 8 mutations are risk factors for developing liver disease of multiple etiologies
US20040197786A1 (en) Method of examining steroid resnponsiveness
JP2002512041A (ja) 緑内障および前眼部形成不全の診断および予後判定のためのｆｒｅａｃ３遺伝子における新規変異
US20030077587A1 (en) Glaucoma therapeutics and diagnostics
EP0814157A2 (en) Diagnostic marker for variants of presenilin genes associated with Alzheimers Disease and Familial Adult Onset Alzheimers Disease
US20030219761A1 (en) Novel prostate-specific or test-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
WO2001009319A1 (fr) Gene exprime specifiquement dans le muscle cardiaque foetal humain
US6913885B2 (en) Association of dopamine beta-hydroxylase polymorphisms with bipolar disorder
Liang United States Patent te
WO2003008561A2 (en) Genes associated with benign prostatic hyperplasia
MXPA00001252A (en) 1-&agr;-HYDROXYLASE MATERIALS AND METHODS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080710

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110413

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110711

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111012

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120326